Want to see KRYS full AI Analyst Report?
KRYS Stock Chart & Stats
$274.21
-$3.73(-2.33%)
At close: 4:00 PM EST
$274.21
-$3.73(-2.33%)
Day’s Range― - ―
52-Week Range$130.50 - $382.54
Previous CloseN/A
Volume44.50K
Average Volume (3M)330.75K
Market Cap
$10.94B
Enterprise Value$9.58B
Total Cash (Recent Filing)$823.40M
Total Debt (Recent Filing)$9.11M
Price to Earnings (P/E)46.6
Beta0.73
Next Earnings
Aug 10, 2026EPS Estimate
1.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.75
Shares Outstanding29,479,755
10 Day Avg. Volume346,607
30 Day Avg. Volume330,745
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue22.96
Enterprise Value/Gross Profit24.74
Enterprise Value/Ebitda47.74
Forecast
1Y Price Target
$340.50Price Target Upside24.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)7.67
Revenue Forecast (FY)$519.18M
Bulls Say, Bears Say
Bulls Say
High Gross Margin & ProfitabilityKrystal’s unusually high gross margins and strong operating/net margins reflect durable manufacturing economics for its topical gene therapy and indicate robust unit economics. Sustained margins support reinvestment into R&D and commercial scale, cushioning the business against cyclical revenue swings and enabling funding of pipeline programs without reliance on external financing.
Strong Cash Generation & Conservative Balance SheetVery strong free cash flow and a >$1B cash/investment balance combined with near-zero debt give Krystal durable financial flexibility. This cash cushion funds multiple clinical readouts, international launches and commercial expansion while minimizing dilution or refinancing risk, materially reducing execution risk over the medium term.
Commercial Traction And Market PositionStrong early adoption—high reimbursement approvals, expanding prescriber base and majority share in an identified rare‑disease patient pool—reflects a durable commercial moat in a small, specialist market. International uptake and recurring prescriptions create a steady revenue base and validate the company’s commercial model for further geographic expansion.
Bears Say
Quarterly Revenue UnpredictabilityStructural insurance churn and the maintenance/start‑stop nature of treatment create recurring quarter-to-quarter revenue volatility. This reduces forecasting visibility, complicates resource planning and can mask underlying demand trends, making it harder to assess sustainable revenue growth even if long‑term adoption improves.
European Pricing & Reimbursement UncertaintyUnresolved pricing and reimbursement outcomes in major European markets are structural bottlenecks for international scaling. Delays or unfavorable pricing in Germany, France and other markets could materially reduce addressable revenue, compress margins abroad and slow the company’s planned geographic expansion over the coming 2–6 months and beyond.
Short Track Record & Prior LossesThe recent profitability and cash generation follow several years of material operating losses, indicating a short track record of sustained earnings power. If commercial access, competitive dynamics, or regulatory setbacks emerge, earnings could revert, so current results may be less durable than longer‑tenured profit histories imply.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech, Inc.’s price range in the past 12 months?
Krystal Biotech, Inc. lowest stock price was $130.50 and its highest was $382.54 in the past 12 months.
What is Krystal Biotech, Inc.’s market cap?
Krystal Biotech, Inc.’s market cap is $10.94B.
When is Krystal Biotech, Inc.’s upcoming earnings report date?
Krystal Biotech, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 30 days.
How were Krystal Biotech, Inc.’s earnings last quarter?
Krystal Biotech, Inc. released its earnings results on May 04, 2026. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.34.
Is Krystal Biotech, Inc. overvalued?
According to Wall Street analysts Krystal Biotech, Inc.’s price is currently Undervalued.
Does Krystal Biotech, Inc. pay dividends?
Krystal Biotech, Inc. does not currently pay dividends.
What is Krystal Biotech, Inc.’s EPS estimate?
Krystal Biotech, Inc.’s EPS estimate is 1.77.
How many shares outstanding does Krystal Biotech, Inc. have?
Krystal Biotech, Inc. has 29,479,755 shares outstanding.
What happened to Krystal Biotech, Inc.’s price movement after its last earnings report?
Krystal Biotech, Inc. reported an EPS of $1.83 in its last earnings report, beating expectations of $1.49. Following the earnings report the stock price went up 7.86%.
Which hedge fund is a major shareholder of Krystal Biotech, Inc.?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$340.50 (24.17% Upside)
$340.50 (24.17% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 30.5%
Last 30 Days ▲ 30.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
149.32%
12-Months-Change
Fundamentals
Return on Equity
19.25%
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Company Description
Krystal Biotech, Inc.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
KRYS Company Deck
KRYS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum, robust profitability, a growing international launch and a busy clinical pipeline with multiple near-term readouts and regulatory designations — balanced by operational challenges including insurance switchovers, start-stop treatment dynamics, rising G&A, certain program-specific regulatory/timing requirements, and ongoing European pricing negotiations. Overall the positives (revenue growth, high gross margin, strong cash position, multiple upcoming data readouts and regulatory designations) materially outweigh the operational and timing headwinds described.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$340.50
▲(24.17% Upside)
Technical Analysis
Ownership Overview
11.14% Insiders
30.42% Mutual Funds
0.45% Other Institutional Investors
32.12% Public Companies and Individual Investors